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Stem cell treatment of dystrophic dogs
Arising from: M. Sampaolesi et al. Nature 444, 574–579 (2006)
Human muscular dystrophies are devastating and incurable inhe-
rited diseases. Hopes of progress towards therapy of muscular dys-
trophies were aroused when Sampaolesi et al.1 reported ‘‘extensive
recovery of dystrophin expression, normal muscle…function’’, and
‘‘remarkable clinical amelioration’’ in golden retriever muscular dys-
trophy dogs treated with ‘mesoangioblasts’. Here I re-examine their
results, showing how their assessments might be flawed and their
conclusions overstated. Further studies will be required to evaluate
fully the clinical potential of this work.
My first concern is that control and test dogs were not matched for
disease characteristics at the start of treatment to avoid inadvertently
biased groupings in small experimental cohorts, where extensive
individual variations exist. Also, the authors’ evaluations were not
blinded. For example, their Supplementary Videos1 seem to show
greater human encouragement of treated compared with untreated
dogs, so functional recovery may not be independently verifiable by
viewers, especially the ‘‘striking improvement of motility’’ in the
older dogs treated with mesoangioblasts.
Second, Fig. 5a of Sampaolesi et al.1 indicates that muscle strength
declined, rather thanwasmaintained as they imply, in the treated legs
of all dystrophic dogs in which it was assessed. At later time points,
strength was always less than at 5months. Between the ages of 5 and 9
months, the averaged decline in strength of the two older treated dogs
was,40% (,0.079 to,0.048 kg21 (%)), evenmore than the,25%
decline in the control untreated dystrophic dog over the same period.
Against this real ,40% decline, purported improvements of ,50%
and ,80% in treated leg-muscle strength relative to contralateral,
untreated muscles of these two dogs (Fig. 5b of Sampaolesi et al.1) are
misleading and probably explained by simultaneous declines in
contralateral muscle strength of ,60% and ,67%, respectively.
Third, the dogs Valgus, Varus and Vaccin each received 53 107
mesoangioblasts per treatment, but these were infused into the aortic
arch of Valgus and the left femoral artery of the others. At biopsy,
,30–70% of fibres in sections of Valgus’ left sartorius and gastroc-
nemius muscles appeared to be dystrophin-positive (Fig. 4a of
Sampaolesi et al.1), whereas the equivalent dystrophin-positive pro-
portion of Varus’ left sartorius was,0–10%, and that of Vaccin’s left
gastrocnemius was only 0–5%. Numbers of mesoangioblasts reach-
ing the lower left leg from upper aortic infusion, after major systemic
blood diversions2, should have been,10 times less than from direct
femoral infusion. However, no assessed muscles of Valgus had
fewer—and certainly not 10 times fewer—dystrophin-positive fibres
than corresponding muscles of Varus or Vaccin. Moreover, some
of the untreated muscles of Varus and Vaccin revealed up to 50%
dystrophin-positive fibres (Fig. 4a of Sampaolesi et al.1).
Minimal mesoangioblast recirculation3 cannot easily explain these
anomalies, whereas dystrophin-positive fibres in both treated and
untreated muscles might represent false positives or revertants4,
rather than evidence of mesoangioblast engraftment. Control
biopsies from pre-treatment and untreated dystrophic dogs4 would
have allowed these possibilities to be differentiated. Alternatively, if
recirculation and engraftment is responsible for similar percentages
of dystrophin-positive fibres in treated and ‘untreated’ tibialis cra-
nialis muscles (Fig. 4a of Sampaolesi et al.1), then contrasting their
strengths (Fig. 5b of Sampaolesi et al.1) is unfounded.
There is an indicator of benefit arising from this trial, although it
is, perhaps, due to concurrent immunosuppression rather than to
mesoangioblasts. Supplementary Fig. 7 of Sampaolesi et al.1 shows
that levels of the muscle-breakdown marker serum creatine kinase
decreased markedly soon after initiating immunosuppression (as
previously seen in mdx mice5) and before injection of heterologous
mesoangioblasts, whereas in the days immediately after mesoangio-
blast injection, creatine kinase levels varied randomly, decreasing
substantially (.5,000U) in three instances but increasing in five.
This does not support the authors’ hypothesis that creatine kinase
reductions demonstrate mesoangioblast reconstitution of muscle
fibres.
Control dystrophic dogs lived, on average, 129 days longer than six
out of ten treated dogs (123 days longer than those treated with
autologous mesoangioblasts). Three of the four remaining treated
dogs, described as ‘‘well’’ 400 days post natal, ‘‘rapidly lost walking
ability’’ when immunosuppression ceased (257 days post natal for
two of these).
Altogether, the evidence presented by Sampaolesi et al.1 does not
convince me that the dogs benefited frommesoangioblast treatment;
a rigorous demonstration correlating muscle function, dystrophin
expression and mesoangioblast infusion, with adequate controls,
would have been helpful in this regard. It is therefore premature to
consider a clinical trial in humans as a justifiable extension of this
study.
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Bretag1 questions our finding2 that ‘‘dogs benefited frommesoangio-
blast treatment’’. We believe that this scepticism is not supported by
careful examination of our data2.
Golden retriever dogs could not be matched for disease character-
istics because they were chosen at 1month of age, before the appea-
rance of clinical symptoms. Indeed, the dog Vaccine, which did not
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show any clinical amelioration, had by chance the highest muscle
contraction force at the beginning of treatment (Fig. 5a of ref. 2,
green triangle). Dogs were encouraged in all cases: the videos of
control dogs and of Vaccine lack audio but show the instructor
encouraging the dogs with a caress, to which they react by swinging
the tail and moving towards the instructor.
Our Fig. 5a (ref. 2) shows that, after a decrease between 5 and 9
months, contraction force increases again only in those dogs treated
with donor cells; Fig. 5b of ref. 2, which compares treated and
untreated legs of the same animal, shows amelioration of contraction
force in the three animals treated with donor cells and not in the one
treated with autologous cells. In Duchenne muscular dystrophy,
absence of dystrophin causes a reduced force of muscle contraction.
We demonstrated a causal relation between dystrophin expression
and force recovery, showing (Fig. 5c, d of ref. 2) that in the same
muscle, dystrophin-positive fibres have normal force of contraction
whereas dystrophin-negative fibres are as weak as untreated, dys-
trophic fibres2.
Contrary to Bretag’s assertion1, Valgus received about 33 107
mesoangioblasts in the left femoralis artery and 23 107 in the left
subclavian artery. Such a small difference (33 107 cells in the case of
Valgus versus 53 107 cells in standard injections in the femoralis
artery) cannot result in a marked difference in the number of
dystrophin-positive fibres; the low numbers of dystrophin-positive
fibres in Varus’ sartorius may be due to more distal insertion of the
catheter in the femoral artery, so that injected cells may not have
reached the cranial part of the sartorius. Notably, we noticed
and pointed out variable distribution of mesoangioblasts in the
injected muscles. For this reason, we analysed more than 50 indi-
vidual biopsies and found extensive, albeit variable, expression of
dystrophin in treated dogs.
The presence of dystrophin in the contralateral muscles as well is
not due to revertant fibres because an antibody directed against the
mutated domain recognizes dystrophin in the muscles of trans-
planted dogs, confirming that wild-type dystrophin may only derive
from wild-type donor cells. Previously unnoticed3, the biceps
femoralis of one untreated dog shows a clear accumulation of rever-
tant dystrophin, easily distinguishable from the wild-type protein
(Fig. 1).
It is true that the first drop in serum creatine kinase for Valgus,
Varus and Viko followed the first treatment with cyclosporine and is
probably caused by the drug, but all the other declines occur after
infusion of mesoangioblasts and in the continuous presence of the
drug, so cannot be ascribed to it.
The cyclosporine effect is controversial, but Bretag1 quotes the
only claim of benefit from cyclosporine4 and ignores others claiming
deleterious5–7 effects; moreover, the absence of any beneficial cyclos-
porine effect in bone-marrow-transplanted, dystrophic dogs8 is not
mentioned.
Long-term survival was not a goal of this study, as immune sup-
pression was suspended at the end of the experiment. Pathologists
did not find any feature at autopsy that could have related to meso-
angioblast accumulation.
Our results showed extensive dystrophin accumulation, clinical
improvement and force preservation in the best available pre-clinical
model of Duchenne muscular dystrophy. We are confident that
our data are correct and form a suitable basis for future clinical
experimentation.
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Figure 1 | Expression of wild-type dystrophin in dogs transplanted with
wild-type mesoangioblasts. a, Four alternatively processed dystrophin
gene transcripts can be amplified in golden retriever muscular dystrophy
(GRMD) canine muscle tissue9. Only transcripts corresponding to exons
2–10 and 4–13 restore the correct reading frame. Wild type (WT, black)
indicates the full-length dystrophin transcript; black and blue arrows
indicate the position of oligonucleotides9 used for the nested polymerase
chain reaction (PCR). b, Three transcripts are amplified by the nested
RT–PCR analysis: the upper band corresponds to wild-type dystrophin
(black), and the intermediate and lower bands correspond to the two in-
frame transcripts (red and orange, respectively). Note the presence of wild-
type transcript in wild-type dogs (K1PR8 and N8PV5) and in dystrophic,
transplanted dogs (VAL, Valgus; VAR, Varus), but not in untreated (Ctrl2:
VLA and L1PW9) dystrophic dogs. BF, biceps femoralis; TC, tibialis
cranialis. c, Western blot analysis using MANEX7B antibody (recognizing
exons 7/8, a gift from G. Morris) reveals wild-type dystrophin only in
transplanted and wild-type dogs. d, Western blot analysis using DYS2
antibody (recognizing the carboxy terminus) reveals the wild-type
dystrophin as above and a lower molecular mass protein in only one
(asterisk; BF, biceps femoralis) muscle of Vlan (VLA), an untreated,
dystrophic dog that shows a significant amount of revertant dystrophin
without cell transplantation. e, Red Ponceau staining of myosin heavy
chains of western blot shown in d.
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